Trial Profile
A randomized, double-blind, placebo-controlled Phase 3 clinical study evaluating Brinavess versus placebo in patients with recent onset atrial fibrillation (AF)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 24 May 2018
Price :
$35
*
At a glance
- Drugs Vernakalant (Primary)
- Indications Atrial fibrillation
- Focus Therapeutic Use
- 24 May 2018 New trial record
- 17 May 2018 According to a Correvio media release, the company's partner Eddingpharm has enrolled the first patient in this trial.